Salvage treatment of HCV patients by Sofosbuvir, Daclatasvir, Simeprevir and Ribavirin after repeated treatment failures is associated with SVR and reduced risk of hepatocellular carcinoma

被引：0
|
作者：
Hanafy, A. [1 ]
Abd-Elsalam, S. [2 ]
Soliman, S. [3 ]
机构：
[1] Zagazig Univ, Fac Med, Internal Med Hepatol & Endoscopy Div, Zagazig, Egypt
[2] Tanta Univ, Trop Med, Tanta, Egypt
[3] Menoufia Univ, Publ Hlth, Al Minufya, Egypt
来源：
JOURNAL OF HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
10.1016/S0168-8278(18)30805-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-365
引用
收藏
页码：S293 / S294
页数：2
相关论文
共 50 条
  • [31] Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients With HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis
    Hezode, Christophe
    Dore, Gregory J.
    Pianko, Stephen
    Pol, Stanislas
    Stuart, Katherine
    Thompson, Alexander
    Tse, Edmund
    Bhore, Rafia
    Jimenez-Exposito, Maria Jesus
    GASTROENTEROLOGY, 2016, 150 (04) : S1096 - S1096
  • [32] RISK FACTORS AND NATURAL HISTORY OF HEPATOCELLULAR CARCINOMA (HCC): OBSERVATIONS FOLLOWING SUCCESSFUL SOFOSBUVIR-BASED TREATMENT IN HCV PATIENTS WITH CIRRHOSIS
    Reddy, K. Rajender Rajender
    Bittermann, Therese
    Khaddaj-Mallat, Nour
    Zhou, Ingrid
    Zhu, Janine
    Ea, Ryan
    Frenette, Catherine
    Scherbakovsky, Stacey
    Mercier, Renee-Claude
    Zhang, Xu
    Da, Ben L.
    Osinusi, Anu O.
    Muir, Andrew Joseph
    Jacobson, Ira M.
    Mangia, Alessandra
    HEPATOLOGY, 2023, 78 : S1881 - S1883
  • [33] Treatment of HCV with DAAs in cirrhosis: Risk of early de novo hepatocellular carcinoma (HCC) and impact of HCC on SVR.
    Sterling, Richard K.
    Patel, Vaishali
    Kumral, Dennis
    Lewis, Shawn
    Cherian, Reena
    Driscol, Carolyn
    Genther, Kathleen
    Lee, Hannah
    Matherly, Scott
    Stravitz, R. Todd
    Siddiqui, Mohammad S.
    Luketic, Velimir A.
    Puri, Puneet
    Sanyal, Arun J.
    HEPATOLOGY, 2017, 66 : 851A - 851A
  • [34] Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy
    Ruggeri, M.
    Rolli, F. R.
    Kondili, L. A.
    Drago, C.
    De Solda, F.
    Nappi, C.
    Cicchetti, A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (03) : 363 - 374
  • [35] Risk Factors of Hepatocellular Carcinoma After Treatment and Obtaining Sustained Viral Response in HCV Genotype 3 Patients
    Nguyen, Kelvin T.
    Kawamoto, Jenna K.
    Sheinbaum, Alan
    GASTROENTEROLOGY, 2016, 150 (04) : S1064 - S1064
  • [36] Rescue therapy for chronic hepatitis C virus infection after repeated treatment failures: Impact on disease progression and risk of hepatocellular carcinoma
    Hanafy, Amr Shaaban
    Soliman, Shaimaa
    Abd-Elsalam, Sherief
    HEPATOLOGY RESEARCH, 2019, 49 (04) : 377 - 384
  • [37] PEGINTERFERON AND RIBAVIRIN THERAPY IMPROVE PROGNOSIS IN PATIENTS AFTER CURATIVE TREATMENT OF HEPATOCELLULAR CARCINOMA-ASSOCIATED HEPATITIS C
    Tsuchiya, K.
    Asahina, Y.
    Tamaki, N.
    Hirayama, I.
    Yasui, Y.
    Tanaka, T.
    Sato, M.
    Hosokawa, T.
    Ueda, K.
    Ikeda, H.
    Nakanishi, H.
    Itakura, J.
    Kurosaki, M.
    Izumi, N.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S28 - S28
  • [38] Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment
    Sanchez-Torrijos, Yolanda
    Ternero-Vega, Jara Eloisa
    Cepeda-Franco, Carmen
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2017, 109 (10) : 734 - +
  • [39] RESIDUAL HCV-RNA IN LIVER EXPLANTS FROM PATIENTS UNDERGOING SOFOSBUVIR AND RIBAVIRIN TREATMENT WHILE AWAITING LIVER TRANSPLANTATION IS NOT ASSOCIATED WITH HCV RELAPSE
    Gambato, M.
    Perez-del-Pulgar, S.
    Hedskog, C.
    Svarovskia, J.
    Paulson, M. S.
    Denning, J.
    Curry, M. P.
    Caro-Perez, N.
    Londono, M. C.
    Forns, X.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S247 - S247
  • [40] THE IMPACT OF ANTIVIRAL THERAPY FOR HCV ON THE SURVIVAL OF HCC PATIENTS AFTER TREATMENT OF HEPATOCELLULAR CARCINOMA
    Mori, Yuki
    Matsuda, Shuya
    Maekawa, Shinya
    Enomoto, Nobuyuki
    HEPATOLOGY, 2020, 72 : 614A - 615A
12345